StockNews.AI
AMPH
StockNews.AI
12 days

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025

1. Amphastar reported Q2 2025 net revenues of $174.4 million. 2. GAAP net income was $31 million, indicating strong financial performance.

Earnings
+10.13%Current Return
VS
+0.78%S&P 500
$21.6208/07 04:07 PM EDTEvent Start
$23.8108/08 10:36 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The strong revenue and income figures suggest ongoing business health, similar to prior high-performing quarters.

How important is it?

The earnings report provides solid quantitative data indicating potential investor confidence and stock performance.

Why Short Term?

Immediate market reaction expected following the earnings report and conference call.

Related Companies

AMGNBMYPFE
- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9 million, or $0.85 per share, for the second quarter - Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / August 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended June 30, 2025.

Related News